Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects

Journal of Clinical Pharmacology

Volumn 48, Issue 2, 2008, Pages 166-175

  Ahmed, Tausif ^a   Sharma, Pradeep ^a   Gautam, Anirudh ^a   Varshney, Brijesh ^a   Kothari, Monica ^a   Ganguly, Sanjeev ^a   Moehrle, Joerg J ^b   Paliwal, Jyoti ^a   Saha, Nilanjan ^a   Batra, Vijay ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

^b International Center Cointrin   (Switzerland)

Author keywords

Healthy; Pharmacokinetics; Piperaquine; Safety; Subjects

Indexed keywords

PIPERAQUINE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIMALARIALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALF-LIFE; HEADACHE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; QUINOLINES; TABLETS; TANDEM MASS SPECTROMETRY; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 38349174133     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007310384     Document Type: Article

References (14)

1. Davis TME, Hung TY, Sim IK, Karunajeewa HA, Ilett KF Piperaquine: a resurgent antimalarial drug. Drugs. 2005 ; 65: 75-87.
2. Hien TT, Dolecek C., Mai PP, et al. Dihydroartemisininpiperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomized clinical trial. Lancet. 2004 ; 363: 18-22.
3. World Health Organization. Antimalarial Drug Combination Therapy. Geneva, Switzerland: WHO Technical Consultation ; 2001.
4. Hung TY, Davis TME, Ilett KF Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B. 2003 ; 791: 93-101.
5. Hung TY, Davis TME, Ilett KF, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol. 2004 ; 57: 253-262.
6. Sim IK, Davis TME, Ilett KF Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother. 2005 ; 49: 2407-2411.
7. Roshammar D., Hai TN, Hietala SF, Huong NV, Ashton M. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol. 2005 ; 62: 335-341.
8. Sheng N., Jiang W., Tang HL Pre-clinical toxical study of new antimalarial agents: II. Piperaquine phosphate and its compound 'Preventive no. 3.' Acad J Second Mil Med Coll. 1981 ; 1: 40-46.
9. Zhao HJ, Xia YY, Zheng Z. Pre-clinical toxicity study of new antimalarial agents: IV. Liver ultrastructure changes affected by antimalarial agent, compound tablet of piperaquine phosphate and sulfadoxine. Acad J Second Mil Med Coll. 1981 ; 1: 47-48.
10. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research ; 2001.
11. Gough K., Hutchison M., Keene O., et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inform J. 1995 ; 29: 1039-1048.
12. Chen Q., Deng J., Wu D. Study on absorption, distribution and excretion of 14C-piperaquine phosphate and 14C-piperaquine in mice. Pharm Ind. 1979 ; 8: 19-23.
13. Tarning J., Lindegardh N., Anneberg A., et al. Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother. 2005 ; 49: 5127-5128.
14. Lindegardh N., White NJ, Day NPJ. High throughput assay for the determination of piperaquine in plasma. J Pharm Biomed Anal. 2005 ; 39: 601-605.